 
  
Title:  Shifting Perspectives: Enhancing outcomes in adolescent anorexia 
nervosa with cognitive remediation therapy  
 
Short Title  Shifting Perspectives  
Drug or Device 
Name(s):  N/A 
FDA IND  N/A 
Regulatory Sponsor:  National Institutes of Health  
eIRB Number   
Protocol Date:  February 24 , 2021 
Amendment 1 Date: 10 July 2019  Amendment 3 Date:  
Amendment 2 Date:  17 July 2019  Amendment 4 Date:  
 
 
 
 
Study Principal Investigator  
C. Alix Timko, PhD  
The Children’s Hospi[INVESTIGATOR_137061]’s Center for Pediatric Research, 8 -212 
Philadelphia, PA, [ZIP_CODE] 
Phone 267- 426-5467  
email: [EMAIL_2815]  
 
    
   
   ii 
TABLE OF CONTENTS  
Table of Contents  ................................................................................................................... ii 
Abbreviations and Definitions of Terms ............................................................................. iv 
Abstract . ................................................................................................................................. v 
Table 1: Schedule of Study Procedures  ............................................................................. vii 
Figure 1: Study Diagram  ....................................................................................................... x 
[ADDRESS_155622] OR INTERVENTION  ................................... 12 
1.2.1 Family Based Treatment (FBT) ..................................................................................................... 12 
1.2.2 Cognitive Remediation Therapy  .................................................................................................... 12 
1.3 RELEVANT LITERATURE AND DATA ................................................................................................... 13 
1.4 COMPLIANCE STATEMENT  .................................................................................................................. 14 
2 STUDY OBJECTIVES  ............................................................................................................................ 14 
2.1 PRIMARY OBJECTIVE (OR AIM) .......................................................................................................... 14 
2.2 SECONDARY OBJECTIVES (OR AIM) .................................................................................................... 15 
3 INVESTIGATIONAL PLAN  .................................................................................................................. 15 
3.1 GENERAL SCHEMA OF STUDY DESIGN  ............................................................................................... 15 
3.1.1 Screening Phase  ............................................................................................................................ 15 
3.1.2 Study Intake  ................................................................................................................................... 15 
3.1.3 Study Treatment Phase (start of the study intervention)  ............................................................... [ADDRESS_155623] Treatment Follow -up ............................................................................................................. 17 
3.2 ALLOCATION TO TREATMENT GROUPS AND BLINDING  ...................................................................... 17 
3.3 STUDY DURATION , ENROLLMENT AND NUMBER OF SITES .................................................................  17 
3.3.1 Duration of Study Participation  .................................................................................................... 17 
3.3.2 Total Number of Study Sites/Total Number of Subjects Projected ................................................ 18 
3.4 STUDY POPULATION  ........................................................................................................................... 18 
3.4.1 Inclusion Criteria (Adolescent)  ..................................................................................................... 18 
3.4.2 Inclusion Criteria (Parents)  .......................................................................................................... 18 
3.4.3 Exclusion Criteria (Adolescent)  .................................................................................................... 18 
3.4.4 Exclusion Criteria (Parents)  ......................................................................................................... 19 
4 STUDY PROCEDURES  .......................................................................................................................... 19 
4.1 STUDY INTAKE (VISIT 0) .................................................................................................................... 19 
4.2 STUDY TREATMENT PHASE  ................................................................................................................ 20 
4.2.1 Visit 1 -8, 10 -12, 14- 17................................................................................................................... 20 
4.2.2 Visit 4  ............................................................................................................................................ 20 
4.2.3 Visit 9  ............................................................................................................................................ 20 
4.2.4 Visit 13  .......................................................................................................................................... 20 
4.2.5 End of treatment evaluation (Visit 18)  .......................................................................................... [ADDRESS_155624] COMPLETION /WITHDRAWAL  ............................................................................................... [ADDRESS_155625] Review  ................................................................................................................. 22 
5.1.2 Other Evaluations, Measures  ........................................................................................................ 22 
5.2 EFFICACY EVALUATIONS  ................................................................................................................... 28 
5.3 SAFETY EVALUATION  ......................................................................................................................... 28 
6 STATISTICAL CONSIDERATIONS  .................................................................................................... 28 
6.1 PRIMARY ENDPOINT  ........................................................................................................................... 28 
6.2 SECONDARY ENDPOINTS  .................................................................................................................... 29 
6.3 STATISTICAL METHODS ...................................................................................................................... 29 
6.3.1 Baseline Data  ................................................................................................................................ 29 
6.3.2 Safety Analysis  .............................................................................................................................. 29 
6.4 SAMPLE SIZE AND POWER  .................................................................................................................. 29 
7 STUDY MEDICATION (STUDY DEVICE OR OTHER STUDY INTERVENTION)  .................... 31 
7.1 DESCRIPTION  ...................................................................................................................................... 31 
7.2 FBT .................................................................................................................................................... 31 
7.3 CRT  ................................................................................................................................................... 31 
7.3.1 Treatment Compliance and Adherence  ......................................................................................... 31 
8 SAFETY MANAGEMENT  ..................................................................................................................... 32 
8.1 CLINICAL ADVERSE EVENTS  .............................................................................................................. 32 
8.2 ADVERSE EVENT REPORTING  ............................................................................................................. 32 
8.3 MEDICAL EMERGENCIES  .................................................................................................................... 32 
9 STUDY ADMINISTRATION ................................................................................................................. 33 
9.1 TREATMENT ASSIGNMENT METHODS .................................................................................................  33 
9.1.1 Randomization ............................................................................................................................... 33 
9.1.2 Blinding  ......................................................................................................................................... 33 
9.2 DATA COLLECTION AND MANAGEMENT  ............................................................................................ 33 
9.2.1 Data sharing .................................................................................................................................. 33 
9.3 CONFIDENTIALITY  .............................................................................................................................. 34 
9.4 REGULATORY AND ETHICAL CONSIDERATIONS .................................................................................. 34 
9.4.1 Data and Safety Monitoring Plan  .................................................................................................  34 
9.4.2 Risk Assessment  ............................................................................................................................. 35 
9.4.3 Potential Benefits of Trial Participation  ....................................................................................... 36 
9.4.4 Risk-Benefit A ssessment  ................................................................................................................ 36 
9.5 RECRUITMENT STRATEGY  .................................................................................................................. 36 
9.6 INFORMED CONSENT /ASSENT AND HIPAA  AUTHORIZATION  ............................................................ 37 
9.6.1 Waiver of Assent  ............................................................................................................................ 38 
9.7 PAYMENT TO SUBJECTS /FAMILIES  ..................................................................................................... 38 
9.7.1 Reimbursement for travel, parking and meals  .............................................................................. 38 
9.7.2 Payments to parent for time and inconvenience (i.e. compensation)  ............................................ [ADDRESS_155626] for time, effort and inconvenience (i.e. compensation)  ..................................... 39 
9.7.3 Gifts  ............................................................................................................................................... 39 
10 PUBLICATION  ............................................................................................................................... 39 
11 REFERENCES  ................................................................................................................................ 39 
 
    
   
   iv 
ABBREVIATIONS AND DEFINITIONS OF TERMS  
   
AN  Anorexia Nervosa  
AE  Adverse event  
CRT   Cognitive Remediation Training  
FBT  Family Behavioral Treatment  
TBI  Traumatic Brain Injury  
ICH  International Conference on Harmonization  
CHOP   Children’s Hospi[INVESTIGATOR_137062] P  Parent -focused Cognitive Remediation Therapy  
CRT A  Adolescent -focused Cognitive Remediation Therapy  
DSMB   Data Safety and Monitoring Board  
EDATP   Eating Disorder Assessment and Treatment Program  
   
   
   
   
   
   
   
   
   
   
   
   
   
   
    
   
   v 
ABSTRACT . 
Context : (Background)  
Anorexia nervosa (AN) is a severe psychiatric condition; the hallmark features are low body 
weight and difficulties gaining weight. Family based treatment (FBT) is the most effective treatment; however, only 50% of adolescents improve. Cognitive Remediation Therapy (CRT) may augment treatment and improve outcome. The best way to add CRT to FBT remains understudied.  
 
Objectives : (primary and important secondary objectives)  
The primary objectives include determining whether or not Cognitive Remediation Therapy (CRT) can increase set -shifting in parents and/or adolescents with Anorexia Nervosa (AN). 
The second objective is to determine the appropriate dose of CRT needed to achieve positive change in set -shifting.  
 
Study Design:  
Randomized controlled trial with three groups.  
 
Setting/Participants:  
Participants will be 60 adolescents with AN and their families.  Treatment will occur on an outpatient basis at Children’s Hospi[INVESTIGATOR_6684].   
Study Interventions and Measures :  
All adolescent s with AN enrolled in the trial will receive FBT.  Families will be randomized 
to FBT only, Family Based Treatment + Parent Focus Cognitive Remediation Therapy, or Family Based Treatment + Adolescent Focused Cognitive Remediation Therapy. Psychosocial, neurocognitive, and behavioral measures will be collected throughout the study.  
    
   
   vi 
 vii   
   
   TABLE 1: SCHEDULE OF STUDY PROCEDURES  
Study Phase  Screening  Treatment/Intervention  3- and 6 -
month 
follow -
ups and 
12 
optional 
FBT 
sessions  
Visit Number   0 1 2 3 4 5 6 7  8 9 10 11 12 13 14 15 16 17 18 19 20 
Assessment   1    2     3    4     5 6 7 
Informed 
Consent/Assent   X                     
Review 
Inclusion/  
Exclusion 
Criteria  X X                     
Medical Chart 
Review   X X X X X X X X X X X X X X X X X X X X X 
Height and 
Weight   X X X X X X X X X X X X X X X X X X X   
2D:4D 
measurement   X                     
Treatment    X X X X X X X X  X X X  X X X X    
Questionnaire 
Battery     
BRIEF -2#  X         X    X     X X X 
ABOS§  X    X     X    X     X X X 
AESED§  X    X     X    X     X X X 
EDE -Q*  X    X     X    X     X X X 
 viii   
   
   BIS/BAS#  X    X     X    X     X   
BASC -3#  X    X     X    X     X   
ECI§  X    X     X    X     X   
IUS#  X    X     X    X     X   
OCI#  X    X     X    X     X   
DFLEX#  X    X     X    X     X X X 
FamQ§  X    X     X    X     X   
DASS#  X    X     X    X     X   
EDFLIX *  X    X     X    X      X X 
SRQ *  X    X     X    X        
AQ#  X    X     X    X        
CEQ#  X                     
WAI∞      X     X    X     X   
TEQ#                    X   
PVA   X    X     X    X     X X X 
Neurocognitive 
Assessment     
WASI#  X                  X
*   
RCFT#  X         X    X     X   
DKEFS#  X         X    X     X   
LBT*   X         X    X     X   
Buffet 
Challenge *  X             X     X   
Howe’s 
Grocery§  X             X     X   
AAT#   X    X     X    X     X   
§Parent only completes this measure  
*Adolescent only  
 ix   
   
   # Parents and Adolescent complete this measure  
∞ Parent, adolescent, and therapi[INVESTIGATOR_137063]  
 
.
 page x    
   FIGURE 1: STUDY DIAGRAM  
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
  
 
 Visit 0/ Time point 1:  
Consent, Height & Weight, 
Baseline Questionnaires, 2D:4D, 
Neurocognitive Assessment, 
Buffet Challenge & How’s 
Grocery  
Randomization 
FBT alone  FBT + CRT P FBT + CRT A 
Visit 1 -3:  
Treatment  
Visit 4/ Time point 2:  
Treatment & Questionnaires  
Visit 5 -8:  
Treatment  
Visit 9/ Time point 3:  
Questionnaires and Neurocognitive Assessment  
Visit 10 -12:  
Treatment  
Visit 13/ Time point 4:  
Questionnaires and Neurocognitive Assessment, Buffet Challenge & Howe’s Grocery  
Visit 14 -17:  
Treatment  
Visit 18/ Time point 5:  
Questionnaires, Neurocognitive Assessment, Buffet Challenge & Howe’s Grocery  
Visit 19& 20/Time points 6 & 7:  
Medical chart review & Questionnaires  12 optional FBT sessions  
 page 11    
   1 BACKGROUND INFORMATION AND RATIONALE  
Anorexia Nervosa (AN) is a serious eating disorder characterized by [CONTACT_137103].  AN has the highest mortality rate of all psychiatric disorders
1,2 and is associated 
with significant morbidity .1 AN often begins during adolescence3 and early interventi on is key 
in order to prevent a chronic, unremitting course of the disorder .4 To date, there is only one 
intervention with substantial empi[INVESTIGATOR_137064]:  Family Based Treatment .
5,[ADDRESS_155627] reduced behavioral 
flexibility (e.g., extreme perfectionism, perseveration, difficulties in learning new behaviors)[ADDRESS_155628] be associated with an illness, be present within the individual 
regardless of the state of the illness, and are inherited. They are found in family members of the 
proband at a higher rate than in the population and within the family the illness and 
endophenotype are inherited together (co- segregat e).[ADDRESS_155629] a greater likelihood of having cognitive 
inefficiencies that may be exacerbated by [CONTACT_137104]. Increased 
difficulties in set- shifting could lead to greater difficulty implementing FBT at home and poorer 
or less rapid gains for their child. Cognitive Remediation Therapy (CRT) is an adjunctive 
treatment that improves cognitive flexibility and can be used with the parents or child.     
Via struct ured input and repetition, CRT leverages the brain’s natural neuroplasticity and fosters 
changes in brain structure and connections. CRT can be restorative (focusing on decreasing cognitive inefficiencies), compensatory (maximize daily functioning without changing cognitive 
impairments), or metacognitive (monitoring one’s own thinking and subsequently adapting 
behavior to the environment).
29 CRT for AN is metacognitive. The goal of CRT is to target a 
cognitive inefficiency using principles of learning in order to improve functional outcomes (i.e., improving memor y in traumatic brain injury (TBI) significantly improves the probability of a 
return to work).
30-32 CRT has a long history of improving aspects of executive functioning 
leading to positive impacts on behavior across a number of conditions (including, TBI33 
depression,31,34 schizophrenia,35,36 and eating disorders37,38). Recent work in AN indicates that 
CRT can improve eating disorder quality of life and may have a positive impact  on weight 
gain.39,40 CRT addresses many characteristics of adolescents with AN that can make treatment 
more difficult.  
 CRT for AN has an unambiguous target: cognitive flexibility. By [CONTACT_137105] a broader system, treat ment gains can be maximized. Augmenting treatment with CRT 
 page 12    
   can potentially strengthen inherited inefficiencies and/or prevent the worsening of 
neurocognitive abilities due to prolonged malnourishment. Alternatively, as parents are the primary implementers of treatment, targeting their cognitive flexibility can increase their ability to (behaviorally) flexibly respond to contingencies in the environment and implement behavioral plans with their sick child. In turn, parents may be able restore their child’s w eight more quickly 
and with a diet that is more macronutrient varied. Increasing flexibility in either the parent or 
child can impact a larger system of behaviors and lead to improved clinical outcome, including 
more a macronutrient varied diet and subsequent increase in rate of weight gain.   1.[ADDRESS_155630] majority of research has focused on CRT for adolescents, we propose that it may be more impactful to target the adolescent with AN’s parents as parents are the individuals carrying the burden of treatment and re -nourishment of their child. Parent only 
modifications of FBT are effective in increasing weight in adolescents with AN,
41-[ADDRESS_155631] or Intervention  
1.2.1 Family Based Treatment (FBT)  
FBT is a manualized family treatment for adolescents with AN. It is effective for children and 
adolescents aged [ADDRESS_155632] over 3 phases:  
1. Refeeding and Weight Restoration  
2. Returning Control of Eating to the Adolescent  
3. Addressing Adolescent Issues and Treatment Completion  
The PI [INVESTIGATOR_137065].   1.2.2 Cogni tive Remediation Therapy  
CRT is an adjunctive intervention focusing on the development of meta -cognition – teaching 
individuals to think about how they think.44 It involves presenting individuals with a variety of 
 page 13    
   tasks req uiring increasingly complex mental abilities – these include geometric figures, illusions, 
reversing sequences of numbers and letters, completing sorting tasks wherein the rules change, 
and finding various routes on a map.[ADDRESS_155633] on their thought 
processes, and identify steps in problem solving.  CRT has three goals:  
1.       Improve brain function by [CONTACT_137106]  
2.       Encourage individuals to think about their thinking style  
3.       Encourage individuals and families to spend time away from thinking about the 
eating disorder.  
 
CRT can be delivered in individual, family, and group formats .46-48 For this study, we will 
administer CR T to either adolescents or their parents. CRT will be delivered for 45- 60 minutes 
prior to FBT sessions for a total of 15 sessions. Participants in CRT will be given weekly 
homework.  
 
1.3 Relevant Literature and Data  
Anorexia Nervosa (AN) is a life -threatening disorder with a significant impact on the quality 
of life of those afflicted.   Age of onset is typi[INVESTIGATOR_137066]; it significantly alters 
patterns of healthy growth and development in adolescents and can impact the functioning of the 
entire family. Severe starvation during the critical period of adolescence affects all developi[INVESTIGATOR_137067], especially brain development.  Results from longitudinal studies of brain function in 
adults with AN indicate that sufferers have long term dif ficulties with executive functioning and 
demonstrate behavioral rigidity (e.g., perseveration, extreme perfectionism, difficulties in 
learning new behaviors) that reflects underlying neuro- cognitive deficits .18,[ADDRESS_155634] to other forms of treatment .39 It increases cogniti ve flexibility in adult and adolescent 
patients with AN .38,51,52 For adolescents with AN, CRT is generally well received and can result 
in increased motivation to engage in t reatment .52 Parents report feeling as if the rationale for 
CRT helps them  understand their child’s behavioral difficulties .50 A family -based form of CRT 
for adolescents w ith AN facilitated parents’ ability to recognize their own and their child’s 
thinking style and helped the family to develop strategies to cope with these thinking styles .[ADDRESS_155635] weight more. Inefficiencies in cognitive 
flexibility are likely inherited; thus, it is reasonable to assume that parents may also struggle 
with flexibility.  Prolonged stress (such as having a child with a potentially lethal illness) can decrease flexibility and narrow behavioral repertoires in face of threat.
53-[ADDRESS_155636] cognitive inefficiencies, they likely experience a state- based reduction in flexibility. 
Whether state, trait, or combination of both – difficulties in cognitive and behavioral flexibility 
can translate into more difficulties implementing exposure to symptom specific stimuli and 
greater symptom accommodation which leads to less macronutrient variation and a slower rate 
of weight gain. Given that parental control of eating is a strong predictor of weight gain,56 
augmenting treatment with CRT to maximize their ability to do so has the potential to increase the number of adolescents who reach remission.  
 
The purpose  of this study is to further investigate the role of CRT in the treatment of adolescent 
AN.  The goal of this study is to determine whether or CRT increases flexi bility  in adolescents or 
parents, if this increase is more than what is observed in FBT alone, and what the dose of CRT is 
needed to increase flexibility.   
 
1.4 Compliance Statement  
This study will be conducted in full accordance all applicable Children’s Hospi[INVESTIGATOR_137068] s and 
regulations including 45 CFR 46, and the Good Clinical Practice: Consolidated Guideline approved by [CONTACT_8639] (ICH). All epi[INVESTIGATOR_48478].  
 The investigators will perform the study in ac cordance with this protocol, will obtain consent and 
assent, and will report unanticipated problems involving risks to subjects or others in accordance with The Children’s Hospi[INVESTIGATOR_137069]. C ollection, recording, and reporting of data will be accurate and will ensure the 
privacy, health, and welfare of research subjects during and after the study.   2 STUDY OBJECTIVES  
The purpose of the study is to determine whether or not augmenting FBT with CR T for parents 
or adolescents significantly improves cognitive flexibility and the dose required to do so.   2.1 Primary Objective (or Aim)  
Aim 1:   To identify whether or not it more impactful to add a parent or adolescent 
component of CRT to standard FBT. We hypothesize that both adolescents and parents who receive CRT will have greater increases in cognitive flexibility than those who receive FBT alone. We will examine magnitude of change in cognitive flexibility across groups.  
 Aim 2:  To determine the dose of CRT needed to lead to a medium effect size (increase in 
cognitive flexibility). We will examine the dose of CRT needed to obtain an increase in 
cognitive flexibility equal to a medium effect.  
 page 15    
    
2.2 Secondary Objectives (or Aim)  
• Collect preliminary data on outcome  
 [ADDRESS_155637] in 
participating by [CONTACT_137107]. A  member of the study staff will 
administer a verbal screening over the phone to determine adolescent and parent eligibility.  Al l 
potential participants who appear to meet inclusion will be provided with information about the clinical trial along with other treatment options. Families who are interested will meet with the study coordinator or research assistants, be provided with m ore information, and (if inclusion 
and exclusion criteria are met) scheduled for an intake.  
Parental/guardian permission (informed consent) will be obtained prior to any study procedures taking place.   
 3.1.[ADDRESS_155638].   
 
The intake begins with informed consent.  Once consent is received, every effort will be made to 
ensure the family will complete all aspects of the baseline assessment (see Table 1).   
 Parents and the adolescent will complete a standard questionnaire batte ry, neuro- psychological 
assessment, IQ assessment, and a number of behavioral tasks. In addition, the adolescents will complete a  diagnostic interview to assess eating disorder symptoms. As part of the intake, the 
adolescent will be asked to serve and eat a meal. This will be videotaped.  
 Video -tapi[INVESTIGATOR_137070] a CHOP approved device.  Data will be uploaded to the CHOP 
server and deleted from the device. All videos will be retained for [ADDRESS_155639], who will complete the clinical interview and provide information for and schedule the next session.  Randomization occurs after the clinical interview.  
 Consent and assessments will ideally occur in- person; however, if this is not possible then 
remote consent and assessment will occur. Remote consent will take place on a CHOP -approved 
video conferencing platform, and study staff will review all sections of the informed consent form with families. Families will be sent a link to our REDCap projec t with the informed consent 
form. At the end of the informed consent discussion, families will be asked to e -sign and e -date 
 page [ADDRESS_155640] or assessor.  
  3.1.3 Study Treatment Phase (start of the study intervention)  
After the  baseline assessment/ intake, the family will be randomized to one of three conditions: 
Family Based Treatment (FBT), Parent Focused Cognitive Remediation Therapy + FBT (CRT
P), 
or Adolescent Focused Cognitive Remediation Therapy + FBT (CRT A). Families will have 15 
sessions of the assigned treatment and be assessed at 4 additional time points  (baseline intake + 4 
more is a total of 5 time points) . For treatment, all standard clinical procedures will be followed.  
 
In the event of an unforeseen circumstance whereby [CONTACT_31806]’s presence at CHOP puts the patient, family, and/or CHOP staff at risk, treatment sessions can be done remotely. All treatment sessions done remotely will take place on a CHOP -approved video conferenci ng app, such as 
Vidyo or Skype Business. If treatment sessions are done remotely , we may ask the family  to 
weigh their  child and share this weight with the study therapi[INVESTIGATOR_541]. A note to file is being made for 
every treatment  session  that occurs remotely and w ill be reported to the IRB and DSMB in a 
yearly report . 
 3.1.4 Assessments 
Assessments will occur  at baseline and then  4 additional  times during treatment (total of 5) 
according to the schedule outlined in Table 1. Assessments will be scheduled within a week  of 
the therapy appointment, ideally on the same day to minimize burden on the family. 
Questionnaires can be completed on line prior to coming in for the assessment.   
In the event of an unforeseen circumstance whereby [CONTACT_31806]’s presence at CHOP puts the patient, family, and/or CHOP staff at risk, assessments can be done remotely. All assessment  sessions 
done remotely will take place on a CHOP -approved video conferencing app, such as Vidyo or 
Skype Business. Remote assessments will involve all tasks that do not involve physical 
manipulation of objects and will also not include the buffet challenge. If assessments are done 
remotely, we may ask the family  to weigh their  child and share this weight with the assessor. A 
note to file is being made for every assessment that occurs remotely and will be reported to the 
IRB and DSMB in a yearly report.  
 
3.1.[ADDRESS_155641] T reatment F ollow -up 
After finishing the study, participants will receive questionnaires via link in email (for RedCap) 
and/or paper versions mailed to them. These will be sent approximately 3-  and 6- months after 
completing the study. Families will als o have the option to receive an additional [ADDRESS_155642] at any CHOP affiliated facility (e.g., Roberts Center 
for Pediatric Research, Adolescent Medicine Specialty Care Center, etc). If th e adolescent is 
unable or unwilling to reconsent, they will not be sent questionnaires for completion. Parents, however, will be sent questionnaires.  
 3.2 Allocation to Treatment Groups and Blinding  
The study statistician will facilitate the sequential randomization of participants employing a covariate -adaptive randomization method (using open source free software; OxMaR)
[ADDRESS_155643] 
6-12 months of active treatment. If there is a delay in treatment (brief hospi[INVESTIGATOR_137071], illness, etc.) treatme nt duration may be slightly 
longer.  It is anticipated that all treatment will be complete within  12-14 months of enrollment.  
 Adolescents and their families will be assessed at five time points: 
 
• T
1: neuropsychological assessment, therapy session, questi onnaires, Grocery store 
(parents), Buffet challenge (adolescent)  
• T2: therapy session, questionnaires  
• T3: neuropsychological assessment, questionnaires  
• T4: neuropsychological assessment, questionnaires, Grocery store (parents), Buffet 
challenge (adolescent)  
• T5: questionnaires, neuropsychological assessment, Grocery store (parents), Buffet 
challenge (adolescent)  
 page 18    
   • T6: Medical chart review and questionnaires (to be completed online/ mailed to the 
family, this will take place [ADDRESS_155644] end of primary treatment intervention)  
• T7: Medical chart review and questionnaires (to be completed online/ mailed to the 
family, this will take place [ADDRESS_155645] end of primary treatment intervention)  
 
 3.3.2 Total Number of Study Sites/Total Number of Subjects Projected  
The study will only be conducted at Children’s Hospi[INVESTIGATOR_6684]. 
 It is expected that approximately [ADDRESS_155646] 45 evaluable 
subjects.   3.4 Study Population  
3.4.1 Inclusion Criteria (Adolescent)  
1. Age 12- 18 
2. Currently meets DSM -5 criteria for Anorexia Nervosa  
3. Medically stable for outpatient treatment  
4. Fluent in English 5. No co- morbid condition that would exclude participation (diagnosis of a pervasive 
developmental disability or mental retardation, psychosis, bipolar disorder, substance abuse, or autism spectrum disorder)  
6. Medical clearance from primary care physician and permission to speak to PCP about clinical issues 7. Biological parent s or primary caregivers  willing to engage in treatment and who l ive with the 
adolescent.  
 3.4.2 Inclusion Criteria (Parent s) 
1 Age >18  
2. Child with a diagnos is of AN  
3. Both parents willing  to participate   
4. Fluent in English  5. No co- morbid condition that would exclude participation 
 3.4.3 Exclusion Criteria  (Adolescent)  
1. Ou tside of  age range  
2. Adopted 
3. No more than four sessions of prior CRT in any format  
4. Presence of: pervasive developmental disability, psychosis, bipolar disorder, substance abuse, 
autism spectrum disorder, or intellectual disability.  
5.  Presence of:  a brain disorder or injury (such as TBI) that could impact the ability to engage in 
treatment  
6. Use of anti -psychotic medication during first [ADDRESS_155647].  
 page 19    
     
7. Concurrent psychosocial therapy  
 3.4.4 Exclusion Criteria  (Parents)  
1. Presence of: pervasive developmental disability, psychosis, bipolar disorder, substance abuse, 
autism spectrum disorder, or intellectual disability.  
2. Presence of: a brain disorder or injury (such as TBI) that could impact the ability to engage in 
treatment  
3. Use of anti -psychotic medication during first [ADDRESS_155648].  
4. No more than four sessions of prior CRT in any format  
 Subjects who do not meet all of the enrollment criteria will not be enrolled. Any violations of these criteria will be reported in accordance with IRB Policies and Pr ocedures.  
Patients with AN who receive psychosocial treatment at CHOP are typi[INVESTIGATOR_137072]. Though it is possible that an adolescent will enter the trial and not be followed by [CONTACT_137108]’s adolescent medicine, this is extremely unlikely.  If it does happen, the adolescent will need to be followed by [CONTACT_137109] (standard of care).  
 Concurrent psychosocial therapy for the adole scent  is an exclusionary criterion.  Given the life -
threatening nature of AN, treatment for it is primary.  It is standard of care for the outpatient 
program at CHOP to request that patients discontinue with outside therapy while receiving treatment for th e eating disorder.  In addition to eliminating any confounding effects of outside 
treatment, this practice follows the current standard of care and will be used in this study. If medication is prescribed for the adolescent it is typi[INVESTIGATOR_137073], the 
adolescent’s primary pediatrician, or by [CONTACT_137110].  Visits with psychiatry (either within or outside of CHOP) will be allowed for medication management only.  Any changes in medication will be confirmed with the prescribing physician  or through the medical chart (if at 
CHOP) and noted.    
 4 STUDY PROCEDURES  
4.1 Study Intake (Visit 0)  
• Informed Consent  
• Medical Record Review (without participants)  
• Height and weight  
• Questionnaires  
• Buffet Challenge  
• Howe’s Grocery  
• Neuropsychological and IQ testing 
• 2D:4D measurement  
• Clinical interview  (video recorded)  
• Treatment sessions (audio or video recorded)  
 page 20    
    
4.2 Study Treatment Phase  
General overview of this phase.  
 
4.2.1 Visit 1 -8, 10- 12, 14- 17 
Each visit the family will receive the tr eatment assigned during randomization (FBT, CRT P, or 
CRT A). The following will happen at each session:  
• Height and weight  
• Review of homework  
• Study intervention 
• Medical Record Review (without participants)  
 
4.2.2 Visit 4  
• Questionnaires  (online or in- person)  
• Height  and weight  
• Medical Record Review (without participants)  
4.2.3 Visit 9  
• Medical Record Review (without participants)  
• Height and weight  
• Questionnaires  (online or in- person)  
• Neuropsychological testing 
4.2.4 Visit 13  
• Medical Record Review (without participants)  
• Height and weight  
• Questionnaires  (online or in- person)  
• Buffet Challenge  
• Howe’s Grocery  
• Neuropsychological testing 
4.2.5 End of treatment evaluation  (Visit 18) 
• Medical Record Review (without participants)  
• Questionnaires (online or in- person)  
• Height and Weight  
• Buffet Challenge  
• Howe’s Grocery  
• Neuropsychological and IQ testing 
• Clinical interview  
 
4.2.6 Optional continuation of FBT  
• 12 optional additional sessions of FBT  
 
4.2.7 Visits 19 and 20  
• Medical Chart Review (without participants)  
• Questionnaires (online  or by [CONTACT_2319])  
 
 page [ADDRESS_155649] to speak with the medical provider to 
coordinate care (e.g., the therapi[INVESTIGATOR_137074] a ble to 
return to school, exercise, or sports). In order for this clinical coordination to occur, the physician does not have to be informed of the participant ’s participation in a clinical trial. Whether or not 
the physician is informed of study participat ion is at the participant’s participants’ discretion. As 
the primary treatment provided in this study is FBT and standard of care, there is no reason to expect the physician to think the adolescent is participating in a study.  
4.[ADDRESS_155650] be in line with the 
appropriate treatment.  
 
4.5 Concomitant Medication  
All prior and concomitant medications  used within 30 days prior to the screening visit and 
through the end of the study will be recorded. The dates of administration, dosage, and reason for use will be included.  
 4.6 Hospi[INVESTIGATOR_137075]; this is usually adolescent medicine at CHOP. Should the medical doctor determine that the adolescent needs to be hospi[INVESTIGATOR_137076], this recommendation will be followed. Adolescents will be allowed to return to the trial post- hospi[INVESTIGATOR_059].  Eating disorder symptomatology and weight 
will be assessed post -discharge from hospi[INVESTIGATOR_307].  Any medication changes/additions will be noted.  
If, however, the adolescent needs to be referred to a higher level of care (e.g., i npatient 
treatment), then the adolescent will be removed from treatment in the trial.   4.[ADDRESS_155651] Completion/Withdrawal  
Subjects may withdraw from the study at any time without prejudice to their care.  They may also be discontinued from the study at the dis cretion of the Investigator for lack of adherence to 
study treatment or visit schedules, AEs, or due to need to refer to a higher level of care (inpatient or residential treatment).  The Investigator may also withdraw subjects who violate the study plan, or to protect the subject for reasons of safety or for administrative reasons.  It will be documented whether or not each subject completes the clinical study. If the Investigator becomes aware of any serious, related adverse events after the subject completes or withdraws from the study, they will be recorded in the source documents and on the case report form.  4.[ADDRESS_155652] Review  
Include a listing of the variables that will be ab stracted from the medical chart (paper or 
electronic).  
• Date of birth  
• Height  
• Lowest weight  
• Highest weight  
• DSM -5 criteria for Anorexia Nervosa  
• Expected body weight (i.e., target goal weight for weight restoration)  
• Expected height (for those who have lost linear height)  
• Date of last menstrual period (if menarche has begun)  
• Parental date of birth (necessary for neuropsychological assessment)  
• Race (parental and adolescent)  
• Ethnicity (parental and adolescent)  
• Familial history of eating disorders  
• Parental heigh t and weight  
• Mid-parental height  
• Hormonal levels  
• Vitals  
• Daily Weight  
• Caloric Intake  
• Medication  
5.1.[ADDRESS_155653] demographic information from the adolescent and parents. This includes age, 
date of birth, sex, race/ethnic.  
[IP_ADDRESS] Cognitive flexibility  
Wechsler Abbreviated Scale of Intelligence (WASI;60): The WASI is a nationally 
standardized measure of general intellectual functioning used in clinical, educational, and 
research settings that scores individuals on four subtests: Vocabulary, Similarities, Block Design, 
and Matrix Reasoning.  We will administer the two subscale version of the WASI to calculate 
IQ.  This is necessary to provide a context in which to understand the results of the neuro-
psychological testing.     
Rey-Osterrieth Complex Figure Test (RCFT;
61): The RC FT measures visual -spatial 
perception, construction, non- verbal memory, planning, problem solving, and motor function. 
This test is pen and paper based requiring participants to copy a complex figure. There are two 
important components to the recreation of  the complex figure: recalling it after a brief period of 
time without priming and the copying it. It is valid to use in adolescents with AN .62 It is used as a 
measure of central coherence. Central coherence has been demonstrated to be impaired in some 
adolescents with AN.   
 
 page 23    
   Delis -Kaplan Executive Functioning Scale s (DKEFS;63). The DKEFS is a comprehensive, 
standardized bat tery of assessments of executive functioning that can be used with children and 
adults, ages 8–89 years. It has also been validated for use with adolescents with AN .64 Selected 
subtests administered included:  trail making test, verbal fluency test, color -word interference 
test, and sorting test.  
 
Behavior Rating Inventory of Executive Function -2 (BRIEF -2;65). The BRIEF -2 is an 86 
item questionnaire that assesses executive functioning in children and adolescents aged 5 to 18 
years of age. There is a global executive composit e score as well as subordinate indices 
examining behavioral regulation and metacognition. The Behavioral Regulation index consists of 
subscales measuring inhibition, set -shifting, and emotional control. The Metacognition index 
consists of subscales looking at initiate, working memory, planning and organizing, organization 
of materials, and monitoring one’s own work. Internal reliability has been found to be good with 
an alpha of .96 for the Behavioral Regulation Index and an alpha of .96 for the Metacogniti on 
index. Adolescents will complete this about themselves and parents will complete it about the 
adolescent and themselves.  
[IP_ADDRESS] Weight and Eating Disorder Symptoms  
Anorectic Behavior Observation Scale (ABOS;66). This 30- item self -report measure taps into 
parents’ observations of their child’s disordered eating behavior. This measure has good 
specificity (89.6%) and sensi tivity (90%) in terms of parental report of ED symptoms; and it is 
correlated with other measures of disordered eating behavior. There are three subscales in this measure: eating behavior ( ɑ=0.80), bulimic -like behavior (ɑ=0.69), and hyperactivity (ɑ=0.69) . 
Good internal consistency has been found for each subscale . This measure is completed by 
[CONTACT_137111] s adolescent report of sympotms. 
 
Accommodation and Enabling Scale for Eating Disorders -Revised  (AESED;
67,68). This 41-
item measure gathers information about the enabling behaviors that  family members with a child 
who has an eating disorder engage in. It is a revised version of a measure developed for use with 
adults. The origional measure contains three subscales: avoidance and modifying routine, meal 
ritual, and control of the family. T he origional scale has internal consistency values ranging from 
0.77 to 0.92.  Only parents complete this measure.   
Eating Disorder Examination – Querstionnaire (EDE -Q;
71, 72). The EDE- Q is a 29 -item 
questionnaire that is a self -report version of the Eat ing Disorder Examination (EDE).  We use a 
self-report measure to reduce participant burden yet allow for assessment at specific time points.   
This measure assesses four symptom domains : restraint ( ɑ=0.75), eating (ɑ=0.78), weight 
(ɑ=0.67), and shape conce rns (ɑ=0.79) as well as the presence and severity of specific ED 
behaviors . This will be used to establish diagnosis and remission status. To track change over 
treatment and follow -up, the [ADDRESS_155654] in symptom assessment  for eating disorders.  
 
 page 24    
   [IP_ADDRESS] Behavioral Flexibility  
Howe's grocery . Howe’s grocery is a website that mimics an online grocery store. The store 
contains  8000 products across various categories (e.g., breads, produce, beverages, snack foods). 
Each product is an a ctual product with the exception of store brand "Howe's"  products. Product 
nutrition information and price are accurate as of  February 2018. By [CONTACT_18943] "check out" 
consumers indicate they have finished their shoppi[INVESTIGATOR_137077]. Consumers are not charged for and 
they do not receive  any groceries.  Howe’s grocery has a logging framework that 
allows  researchers have a  granularity of understanding where users click, spend the most time, or 
the sequence of additions and removals from the user’s cart. In this study, parents’ food choices 
in their cart can be analyzed for macronutrient and caloric content. Parents will be asked to do 
three days of meal planning and then “ shop”  for those menu items on- line.  
 
Buffet Challenge.  Adolescents with AN will be presented with a buffet of food options ( See 
Table 2 ). Buffet options were created in collaboration with a nutritionist and generated from 
items in the Food Choice Task.73 We chose to present adolescents with actual food items instead 
of a computerized tas k as there may be a difference between being able to choose more varied 
food on a computer and actually choosing and consuming foods. Food options will include both 
“safe” foods (such as salad, lean protein) and common “fear” foods (pasta, pi[INVESTIGATOR_6107], desserts) . 
Adolescents will approach the buffet, serve food, and consume the meal without coaching or 
support from parents. The meal will be videotaped and the following data collected: time to 
approach buffet, time spent serving food, time eating food, amount of f ood chosen (weight and 
calories), macronutrient profile of food chosen, and amount (calories and macronutrients) eaten. 
We will also code for meal time behaviors reported in Gianini74 (e.g., tearing, staring, 
dissecting). 
 
Approach -Avoidance T ask (AAT): Th e AAT assesses approach -avoidance tendencies. Single 
stimuli are presented to participants on a computer screen. In response to the images, the 
participant presses a computer key.  One key represents a positive valence, or an “approach” response, and the other represents a negative valence, or an “avoidant” response. Unique deduction of stimuli valence, which, for this study, will display as food items. With a keyboard, participants will press one of two buttons for each stimulus presented to them. The images displayed in this AAT will be that of food items (e.g., pi[INVESTIGATOR_137078]) or personal care items (e.g., toothbrush or towel). 
 
Table 2. Buffet Challenge Foods 
(sample)  
grilled chicken  
tofu   doughnuts/brownies  
French fries  
chicken fingers  
veggies  
peanut or almond 
butter  yogurt and granola  
salad bar  
wrap/sandwich bar  
chocolate  
mac and cheese  
plain pasta with red sauce  
pi[INVESTIGATOR_137079] 25    
   [IP_ADDRESS] Comorbid symptoms and potential moderators  
Behavioral Inhibition System and Behavioral Activation System Scales (BIS/BAS;75). The 
behavioral inhibition system (BIS) and behavioral activation system (BAS) scales are self -report 
measures used to examine a patient’s inhibition and activation sensitivity. The scale is composed 
of four  sub scales, one scale to measure BIS sensitivity, and three subscales related to BAS 
sensitivity (Drive, Fun Seeking, and Reward Responsiveness Scales). The BIS component 
measures patient sensitivity to signals of punishment, for example, patients high in BIS 
sensitivity are more responsive to punishment cues and experience greater negative affect 
(anxiety) in situations associated with punishment. The BAS component measures sensitivity to 
signals of reward, for example, patients with high BAS sensitivity are highly responsive to reward cues and experience positive affect. Internal consistency was high for the BIS ( ɑ=0.74), 
BASS Reward Responsiveness (ɑ=0.73), BAS Drive (ɑ=0.76), and BAS Fun Seeking (ɑ=0.66).  
Recently, AN has been hypothesized to be related to abnormalities in reward processing.  
Adolescents will complete this about themselves; parents will complete it about themselves and 
their child.  
 
Behavior Assessment System for Children -3 Parent and Child Version (BASC -3;
76). This is 
[ADDRESS_155655] reliability 
of .81- .89. Both parent and self -report versions are available, allowing for c omparison of parent 
and self observations of behavior. The measure includes both adaptive scales (e.g. Daily Living, 
Social Skills, Functional Communication) and clinical scales (e.g. Depression, Anxiety, Withdrawal, Atypi[INVESTIGATOR_897]). Given that mood disorders and interpersonal deficits often accompany AN, a full assessment of these domains will allow broader based evaluation of treatment. It might also provide information regarding the adolescent’s strengths and allow for tracking of improvement in adaptive are as.  
 Experience of Caregiving Inventory (ECI;
77). This 66- item self -report measure assesses 
caregivers’ perception of their experiences interacting with their child. It includes subscales with both negative (eight subscales) and positive items (two subsca les). This measure is included to 
assess change in parental experience of having an ill child (i.e. greater hope for positive outcome, 
less judgmental of the adolescent). The ECI has demonstrated good construct validity 
(explaining 36% of the variance in s cores on measures assessing general health and copi[INVESTIGATOR_007]) and 
high internal consistency (Cronbach’s alphas ranging from 0.74 to 0.91) among caregivers for 
patients with AN .
69 It is only completed by [CONTACT_3654]. 
 
Intolerance of Uncertainty (IUS;78). The IUS is a 27 item self -report measure that assesses six 
aspects of intolerance to uncertainity, 1) the emotional and behavioral consequences of being 
uncertain, 2) how being uncetain relects on an individuals character, 3) expectations that the future be predictable, 4) frusteration surrounding unpredictability of the future, 5) attempts to control the future, 6) and all or nothing situations when in unceratin situations. Items are measured on a 5 point Likert scale. The IUS showed strong internal consistency ( α = .94) and 
good test -retest reliablity ( r =.74) over a [ADDRESS_155656] good concurrent validity with measures of worry, anxiety, and depression. The IUS will be administered at all time points.
 
 
 page 26    
   Obsessive Compulsive Inventor y (OCI;79). There is an adult (OCI) and child ( C-FOCI ) version 
of this measure. The C -FOCI  is a 17 item self -report questionnaire that assesses presence of 
common obsessions and compulsions. There are two parts to this scale – a symptom checklist 
and a sev erity scale. The adolescen t checks yes or no for the checklist and for the scale endorse 
items according to a range from 0 (none) to 4 (extreme). The internal consistency was acceptable 
for both parts ranging from .76- .79. OCD is highly comorbid with AN  and can appear as rigid 
behavior. Parents will complete the OCI about themselves . This is an 18 item scale using a 5 
point Likert type response that assesses distress associated with obsessions and compulsions. It 
has good internal consistency reliability (.81- .93). Parents will complete the OCI.  
Detail and Flexibility Questionnaire (DFlex;80). The DFlex is a [ADDRESS_155657] been measured in an Austistic sample using the Autism Spectrum Quotient (AQ), and thus  the AQ was used to determine construct validity. A strong correlation 
for cognitive rigidity was shown (r = .72) and a moderate correlation for attention to detail (r = .26). The DFlex is a new measure developed to address both flexibility and central coh erence. It 
will be completed by [CONTACT_137112].   Line Bisection Task ( LBT;
81). The LBT has been widely used as a behavioral measure of visual 
neglect in patients with brain damage. More recently, neuroimaging research has confirmed it can also be used to measure approach motivation in non- clinical populations . In the task 
participan ts mark the perceived mid -point of staggered horizontal lines of the same length in 
millimeters (mm). When participants make errors in marking the midpoint left of the true midpoint these are scored as negative. Meanwhile, positive scores mean greater left  to right 
hemisphere activation. The LBT is being pi[INVESTIGATOR_137080] a behavioral measure of approach -based copi[INVESTIGATOR_007]. It will be completed by [CONTACT_137113].  
 Family Questionnaire (FamQ;
82). Expressed emotion (EE) has traditionally been a ssessed via 
clinical interview, however the interview can be laborious and time consuming. In order to address this issue, the FQ was developed. It is a 20 item self -report measure that includes two 
subscales: criticism and emotional over involvement. Scor es on the FQ have high convergent 
validity with more traditional interview assessments of EE. Test- retest reliability over two weeks 
produced Pearsons correlations of r= 0.84 for the criticism (CC) and r=0.91 for the emotional overinvolvement (EOI) subscal es. Similarly, internal consistency was good, ranging from 0.90-
0.92 for the CC and 0.79 -0.82 for the EOI subscales. Only parents will complete this measure.  
 Depression Anxiety Stress Scale (DASS;
83): The DASS is a 42 -item self -report instrument 
measuring  current symptoms of depression, anxiety, and stress on three separate scales. Higher 
scores on each of the scales indicate higher levels of depression, anxiety, and stress. Among clinical and community populations high internal consistency was found for t he depression 
(ɑ=0.94), anxiety (ɑ=0.87), and stress subscales (ɑ=0.91) . The DASS -[ADDRESS_155658] good convergent reliability with other well validated measures of depression and anxiety (e.g., Beck Depression Inventory, State -Trait Anxiety Inventory).  Parents and adolescents will 
complete this about themselves.   Eating Disorder Flexibility Index  (EDFLIX): The EDFLIX is a 51 -item questionnaire where 
participants use a six -point Likert scale to respond to each question. The EDFLIX ranges in 
 page 27    
   questions, some asking specifically about their eating disorder (e.g., “I need my meals to be 
predictable (time, food, content)” and “I prefer eating the same foods as I usually do”) and others are more abstract (e.g., “I find it difficult to get used to new situations” and “When I am stuck on a task, I am unable to come up with new solutions.”)  
 
Autism Spectrum Quotient (AQ -10): The AQ is a 10 -item questionnaire for parents to 
complete regarding the child’s behavior if their child is between 12 and 15 yea rs old. If the child 
is 16- 18 years old, the child will complete this questionnaire about themself. Additionally, 
parents will complete this questionnaire about their own behavior. The AQ contains a 4- point 
scale, ranging from “definitely agree” to “defini tely disagree.” There are two versions of this 
questionnaire, one for participants aged 12- 15 years old and another for participants aged 16 and 
older. Examples of questions are, “S/he notices patterns in things all the time” and “S/he is good 
at social ch it-chat.”  
 Social Reward Questionnaire (SRQ): There are two versions of the SRQ, one for adults and one for adolescents. W e will administer  the SRQ designed for adolescents (SRQ -A). This 20-
item questionnaire is scored on a 7- point scale, with responses r anging from “Strongly disagree” 
to “strongly agree.” The questionnaire asks participants to rate different statements such as, “I enjoy t reating others fairly” and “I enjoy keepi[INVESTIGATOR_25581] I make to others.”  
 
Parent Versus Anorexia Scale (PVA) :  The PVA is a 7 -item questionnaire for parents to 
complete regarding their own self efficacy to feed their adolescent. They respond to each item on 
a 5 point Likert scale ranging from “strongly disagree” to “strongly agree”. It is aimed at measuring pare ntal efficacy throughout family- based treatment to track changes over time.   
Treatment Credibility/Alliance  
Credibility/Expectancy Questionnaire (CEQ;
84). This [ADDRESS_155659] they will 
improve, due to treatment. The CEQ was designed to be used in clinical outcome trials and was validated on a mixed sample of patients. It has good internal consistency (.85) and test -retest 
reliability (.75 -.82).  
 Worki ng Alliance Inventory (WAI;
85). The WAI is a [ADDRESS_155660] outcome.   
CRT Treatment Evaluation Questionnaire  (TEQ;
86) The TEQ is a [ADDRESS_155661] safety will be monitored by  [CONTACT_20721], weight, parental report of behavior, and 
weekly checks on eating disorder symptoms (EDE short version). Regular contact [CONTACT_137114]’ pediatricians will also occur. When questions may arise about adolescent health, [CONTACT_137122] will  review vital signs, weight gain, and eating disorder symptoms and make 
recommendations vis a vis hospi[INVESTIGATOR_137081] a higher level of care.  
 6 STATISTICAL CONSIDERATIONS  
6.1 Primary Endpoint  
Aim 1:   To identify whether or not it more impactful to add a parent or adolescent 
component of CRT to standard FBT. To assess if CRT engages the target, we will use mixed 3 (treatment) x 2 (time) Multivariate Analysis of Covariance (MANCOVA): one for adolescents,  
one for mothers, and one for fathers.
 The covariate for all analyses is total IQ on the WASI.  
Dependent variables are as follows: Trails Number -Letter Sequencing, Inhibtion, 
Inhibition/Switching, Correct Response Shifting, Category Switching, or Descript ion 1 or 2 and 
Shift on the BRIEF -2. We will follow these steps:  
1. Conduct omnibus MANCOVA and evaluate significance. If not significant, stop and move to next analysis.  
2. If the omnibus test is significant, we will conduct individual 2 (treatment) X 2  (time) Analysis 
of Covariance (ANCOVA) to determine which dependent variable had significant change, with 
IQ again as the covariate.  
3. Each assessment of the target (DV) will be examined. Results will inform the Go/No -Go 
Decision as described in Table 6 . 
These three steps will be repeated for adolescents, mothers, and fathers. We will include all 
three groups in the initial MANCOVA and follow -up with planned comparisons (ANCOVA) of 
FBT vs the appropriate CRT condition. In all analyses, we will focus on t he within and between-
group effects, examining interaction effects are not necessary to evaluate the target. As we have 
chosen measures demonstrated to change with CRT,
40,87 -90 we will maintain α=0.[ADDRESS_155662] adolescents whose  parents receive CRT or parents whose 
adolescents receive CRT to demonstrate increases in flexibility. However, should the planned ANCOVAs not be significant, we will be able to explore other possible group differences. Additionally, we will explore the re lationship between dependent variables via discriminant 
analysis. These additional methods to examine the data will not factor into the Go/No- Go 
decision, but will enhance the depth of our understanding of the data and contribute to our understanding of ne urocognition in AN.  
Aim 2:  To determine the dose of CRT needed to lead to a medium effect size. Some research 
indicates that ≥8 sessions of CRT are necessary for improvement in cognitive flexibility with AN.
92 It is unknown how many sessions will be neede d for significant change in parents of 
 page 29    
   adolescents with AN. To determine optimal dose, we will model change across the 15 sessions 
using latent growth curve modeling (LGCM). LGCM will allow us to analyze individual and average trajectory and model linear and quadratic trend. We will visually assess for the point (dose) at which there is a significant decrease in the rate of improvement (quadratic). P arameter 
estimation will employ Maximum Likelihood (ML) estimation.
93,94 We will evaluate model fit 
using chi -square (χ2), Comparative Fit Index (CFI), Standardized Root Mean Squared Residual 
(SRMR), and Root Mean Squared Error of Approximation (RMSEA).95 The following values are 
indicative of acceptable fit between the model and the observed data variance/covariance 
matrixes: CFI, SRMR, and RMSEA, < .95, < .80, and < .05, respectively.  We will assess and 
compare different models using BIC and novel crite ria such as Scaled Unit Information Prior 
BIC.96,97 Examining standardized model residuals in addition to global fit indices (GFI) permits 
us to identify model misspecification even if GFI values suggest adequate fit.95  
6.2 Secondary Endpoints  
Secondary endpoints include preliminary examination of symptom change (EDE, ABOS) and 
rate of weight gain.  
 
6.[ADDRESS_155663] descriptive summaries (e.g. means and standard deviations for continuous variables such as age and percentages for categorical variables such as gender).  
 6.3.[ADDRESS_155664] (R61), our sa mple size 
estimation is based on a mixed MANCOVA design with two repeated measures from baseline to end-of-treatment (EOT; within subjects component) and three groups (CRT
p, CRT A, and FBT; 
between subjects component). Based on a review of the literature, w e are powering for a medium 
effect size. Our effect size estimate is Cohen’s f statistic.[ADDRESS_155665] size estimate is a ratio of 
variation explained to that unexplained by [CONTACT_10994] (treatment groups), and is expressed as 
follows: 𝑓𝑓 =�𝜂𝜂2
(1−𝜂𝜂2), where 𝜂𝜂2=𝜎𝜎𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚2
𝜎𝜎𝑇𝑇𝑚𝑚𝑇𝑇𝑇𝑇𝑚𝑚2; proportion of variability due to the model.99,[ADDRESS_155666]. For all analyses, we specified an α=0.15, two time points, and a correlation between measures of .3 (based on unpublished da ta). The anticipated N 
accounts for dropouts (i.e., number enrolled will be higher).  
Power analysis Aim 2. Using M plus 7.2,94 we conducted a LGCM  Monte Carlo simulation with 
1000 replications94,101 -103 to determine power to identify CRT P/A dosage based on a half standard 
 page 30    
   deviation increase (rate of change; slope) from baseline (effect size) above FBT. With [ADDRESS_155667] error bias were ≤ 5%, confidence interval coverage ≥ 90%, and power = 0.59
.   
 
 page 31    
   7 STUDY MEDICATION (STUDY DEVICE OR OTHER STUDY INTERVENTION)  
7.1 Description  
All treatment will be delivered  by a doctoral - or Master’s -level psychologist. All therapi[INVESTIGATOR_137082]. 
These clinicians will be designated and added to section 1.02 of the eIRB  once hired . Treatment 
will be delivered at the Robert’s Center for Pediatric Research.  
 7.2 FBT  
FBT was described in section 1.2.1.  15 sessions of FBT will be administered over  the course of 
6-12 months , with the option to participate in an additional 12 follow -up FBT sessions . 
 7.3 CRT  
CRT  was described in section 1.2.2. 15 sessions of CRT will be administered over the course of 
6 months for families in CRT
A and CRT P.  
 7.3.1 Treatment Compliance and Adherence 
Treatment Fidelity.  Sessions will be conducted by [CONTACT_68826] - or Master’s -level therapi[INVESTIGATOR_137083]. Prior to study start, therapi[INVESTIGATOR_137084] a [ADDRESS_155668] day reviews FBT; d ays [ADDRESS_155669]. Timko will provide weekly 
supervision of FBT and CRT.  
Treatment sessions will be videotaped and a random selection of 20% tapes per patient will be 
reviewed for adherence to FBT and CRT. FBT fidelity will be assessed u sing published 
methods,
104 CRT fidelity will be ass essed by [CONTACT_137115] [INVESTIGATOR_137085] a recent 
CRT pi[INVESTIGATOR_799]. A trained master’s level research assistant will score tapes for adherence and review weekly with [CONTACT_60577]. In the event that a participant receives care that is a significant deviation from protocol (lack of adequate adherence ratings on more than 20% of sessions), this participant’s data will be removed from analyses. If drift occurs, therapi[INVESTIGATOR_137086] a refresher training  session, the next three sessions will be reviewed and if improvement to 
criterion does not occur, the therapi[INVESTIGATOR_137087].  
Missed sessions. Should a therapi[INVESTIGATOR_137088] a session (due to illness or vacation) the session will 
be rescheduled, the  other therapi[INVESTIGATOR_137089] a week is not missed , or the 
family will be asked to schedule two sessions the following week.  Should the family need to cancel, all attempts will be made to reschedule within the week to ensure the family stay s on 
schedule.  If an appointment cannot be rescheduled within the week, the family will have two 
sessions scheduled the following week.  
 
 page 32    
   8 SAFETY MANAGEMENT  
 
8.1 Clinical Adverse Events  
Clinical adverse events (AEs) will be monitored throughout the study.   
8.2 Adverse Event Reporting  
Since the study procedures are not greater than minimal risk, SAEs are not expected. If any 
unanticipated problems related to the research involving risks to subjects or others happen during the course of this study (including SAEs) they will be reported to the IRB in accordance with CHOP IRB SOP 408: Unanticipated Problems Involving Risks to Subjects. AEs that are not serious but that are notable and could invol ve risks to subjects will be summarized in narrative or 
other format and submitted to the IRB at the time of continuing review.  
 8.3 Medical Emergencies  
As hospi[INVESTIGATOR_137090], hospi[INVESTIGATOR_137091]. A summary of all hospi[INVESTIGATOR_137092].  
 page 33    
   9 STUDY ADMINISTRATION 
9.1 Treatment Assignment Methods  
9.1.1 Randomization  
Procedures for randomization were described in Section 3.2.  
 
9.1.2 Blinding  
Research assistants who assess adolescents at each time point will not be aware of their study 
condition.   9.2 Data Collection and Management  
All data (with the exception of DKEFS, WASI, BRIEF, and BASC as these have standardized forms) will be s tored in RedCap.  Scores from these standardized forms will be entered into 
RedCap to ensure all data is in the same place.  
All participants will be given a unique study ID and all study information will be coded using 
this number  (in RedCap and on standa rdized forms). The master list linking participants with 
their numbers will be stored in a separate RedCap file that only members of the research team 
will have access to .  
RedCap data will be downloaded weekly and stored in a password protected file on the secure 
research server. Only the CRC and PI [INVESTIGATOR_137093]. This is for backup.  
Audio/video files of treatment sessions will be stored on the research server and destroyed after 
study end. These are necessary to ensure treatment fidelity. Only s tudy staff involved in the 
project will have access to these files.  
Data will remain coded until all study procedures are complete and initial findings have been published. A fter [ADDRESS_155670], the PI [INVESTIGATOR_53586] a NIMH Data Reposi tories 
Data Submission Agreement. Per guidelines, data will be shared in two tiers: raw data while the study is on- going and analyzed data with publication of results/after the reward period. Once a 
manuscript is published, all analyzed data will be submit ted.  Data will include descriptive/raw 
day from questionnaires, demographic data, and data abstracted from the medical chart. We will also include raw and standard scores for the neuropsychological assessments used in the course of this study. Per require ments, raw data will be submitted bi- annually, starting [ADDRESS_155671] of behavioral data (Howe’s Grocery and Buffet Challenge), we will work with staff in order to ensure appropriate and smooth submission of data.  Vi deo 
recordings of the buffet challenge will not be submitted. Additionally, video recording of the clinical interviews will not be submitted.  We will ensure that all participants will have a Global Unique Identifier and each data set will be associated wi th the appropriate publications .  
 
The PI [INVESTIGATOR_137094]. As some researchers may not have access to or wish to access the National Database, 
 page [ADDRESS_155672] the data from the PI [INVESTIGATOR_137095]. Requests are necessary given the nature 
of the data; although it will be de -identified, it will contain s ensitive health information about the 
participants.  
 
9.[ADDRESS_155673] obtaining IRB approval. The investigator will obtain a data use agreement between the provider (the PI) of the data and any recipi[INVESTIGATOR_5772] (including others at CHOP) before sharing a limited dataset (PHI limited to dates and zip codes).  
 9.[ADDRESS_155674]. Timko will meet as needed with the Medical Safety Officer to review new patients or any concerns.   
 We will monitor participants for the occurrence of any adverse events associated with data collection and participation and will report these events as directed by [CONTACT_137116] (AE) reporting policies. Events will be reported promptly to [CONTACT_60577] (PI) and the study coordinator who will make provisions to respond appropriately, ensuring referral to medical/professional resources, as needed.  
 [IP_ADDRESS] Breach of Confidentialit y.  
The PI [INVESTIGATOR_137096]. Annually, research staff will be required to sign a statement acknowledging their receipt and understanding of the confidentiality requirements and pledging to maintain confidentiality of the data to which they have access. If a breach of confidentiality is identified, the PI [INVESTIGATOR_137097].  
 [IP_ADDRESS] Continuous Quality Assurance and Quality Control Procedures (QA/QC)  
QA/QC wil l be implemented to ensure compliance with study requirements in areas including 
recruitment and data collection. Quality control activities will be performed regularly on all electronic data and participant files to ensure that all data collected is compl ete and accurate. 
These will include the reconciliation of data forms, verification of codes and labels, and careful 
 page [ADDRESS_155675] clinic practice is for therapi[INVESTIGATOR_137098], global symptom severity, and symptom improvement at each visit and this information becomes part of patients’ permanent clinical records. Participants in the study will have CHOP behavioral health emergency numbers.  
[IP_ADDRESS] Data and Safety Monitoring Board  
This study will be conducted under the guidance of a Data Safety and Monitoring Board (DSMB). The DSMB will act in an advisory capacity to monitor participant safety, evaluate the progress of the study, and review procedures for maintaining the confidentiality of data and the quality of data collection, management, and analyses. The Board will be led by a chair and at least [ADDRESS_155676] expertise in a n area relevant to the study 
aims, examples are: adolescent health research, behavioral treatment, neuropsychology/neurocognition, treatment implementation, statistical analysis, adolescent development, and/or eating disorders. DSMB members will have no di rect involvement with the 
study investigators or intervention. The board will meet [ADDRESS_155677] meeting will occur prior to initiation of study activitie s to review and approve the study protocol and safety 
monitoring and reporting plan. Subsequent meetings will occur 6 months after the start of study recruitment, 12 months after the start of study recruitment, and again after all treatment has ended and d ata analysis has begun. Ideally, all meetings will be in person, however, remote 
participation (i.e., via Skype or Zoom). A detailed DSMB Charter will be developed that provides a detailed list of DSMB responsibilities.  
 The DSMB will receive a data and safety monitoring report at each scheduled meeting. This report will include the following sections: Overview of DSMB, Study Status, Study Recruitment, Study Enrollment, Study Randomization, Participant Characteristics, Study Data Collection, Regulatory Compliance, Adverse Events and Protocol Deviations, Quality Control and Data Management, Data Analysis, Sample Size and Power Analysis, Outcome Data, Recent Publications of Relevance, and Challenges and Resolutions. In these reports, data and discussion will b e confidential and participant identities will not be revealed.  
9.4.[ADDRESS_155678] adolescents should gain weight and experience a reduction in eating disorder symptoms. CRT is highly acceptable and has been shown to decreas e drop out from treatment.  
 [IP_ADDRESS] Indirect benefit  
More treatments for anorexia are needed, particularly for those who do not fare well in FBT.   
This study investigates whether or not CRT can be a viable augmentation to treatment and for 
whom (parents or child) it has the most benefit.  
9.4.4 Risk -Benefit Assessment  
Risks are minimal. All adolescents will receive family -based treatment – the most recommended 
treatment for adolescents with AN.  Two g roups will receive an additional session of CRT each 
week. Adolescents will be required to have medical care during the course of the study. If they are not improving, recommendations for a higher level of care will be given.  The benefits of finding a way to improve outcomes out -weighs the minimal risk.  
 9.5 Recruitment Strategy  
Eligible participants will be identified through the inpatient and outpatient programs of the Eating  Disorder Assessment and Treatment Program (EDATP) at CHOP . We will also recruit 
through CHOP satellite primary care facilities and online .  
 Adolescents enter our program through three primary pathways: through an outpatient nutrition and medical evaluati on, through an outpatient multidisciplinary evaluation 
(psychology/psychiatry, nutrition, medical), or through hospi[INVESTIGATOR_137099]. Screening for eligibility will occur either at an outpati ent evaluation or during hospi[INVESTIGATOR_137100].  
 Potentially eligible patients identified (those in hospi[INVESTIGATOR_4791] a diagnosis of anorexia or those presenting for an evaluation) will be contact[CONTACT_137117]. If the family is interested, study procedures will be described to the family, including a brief review of inclusion and exclusion criteria. If the family is interested, consent to participate will be coordinated with the clinical intake. Assuming the adolescent is stable for outpatient treatment, they can enter the research study after the intake. The study staff will  only collect private health information as it pertains to determining eligibility 
before consent, per CHOP IRB guidelines. Study staff will not collect any additional private health information without obtaining consent and HIPAA authorization first. As  the Eating 
Disorder Program also has an inpatient program, the list of patients being treated as part of the 
 page [ADDRESS_155679] a limited phone screen to determine eligibility. If the adolescent and parents are eligible to participate, study staff will schedule the family for the baseline assessment.  If the family is not receiving medical care in the EDATP, medical records wi ll be requested from the PCP. The 
medical safety officer (R. Peebles) will review the chart and make a recommendation regarding appropriateness for outpatient care.  
 Additionally, this study will appear in “This Week @ CHOP,” a segment in an internal news letter made available to all CHOP employees. Interested families will be instructed to call 
study staff to determine eligibility, as outlined above.  Furthermore, the study team will be obtaining a list from CHOP’s Department of Biomedical Health Informati cs (DBHI) of Medical Record Numbers (MRNs) of patients with an anorexia 
nervosa diagnosis within the last six months. Should they wish to, the DBHI could obtain this list of MRNs from the Recruitment Enhancement Core (REC), who has already pulled this data . 
Because we do not intend for the REC to act as an honest broker on our study team’s behalf, the REC will supply the DBHI with this information, which will then be supplied to our research team. When this list is obtained, the study team will communicate with eligible families to provide more information about this clinical trial if interested. We chose not to use the REC as an honest broker as we felt that it would potentially be overwhelming for families who have opted not to participate, are already involved in care, or otherwise not appropriate for the study. We will be able to compare the list of MRNs to those who have been screened and only approach those patients who have not been screened, if appropriate. With this approach, we hope to possibly identify adolescents who are being treated in primary care without behavioral health support.  9.6 Informed Consent/Assent and HIPAA Authorization 
Informed consent will be obtained by [CONTACT_60572] s. Consent will take place prior to the 
intake and will occur at Robert’s Center for Pediatric Research prior to the intake. For 
adolescents who are hospi[INVESTIGATOR_137101], consent can occur while they are in hospi[INVESTIGATOR_137102].  
Participants will be a ble to take up to [ADDRESS_155680] will be accommodated.   Any and all questions will be answered by [CONTACT_137118] m 
member reviewing the consent form.  All risks and benefits will be explained. In prior research 
the consent procedure usually takes 30 minutes . 
 page 38    
   The consent form will be signed by [CONTACT_3654], the adolescents, and a member of the study 
team.    HIPAA Authoriza tion will be combined with the consent form. Parents will be given a 
copy of the consent form to take home with them. 
Consent and assent will be obtained from subjects who are 14+ years old and from parents. For 
all other adolescents, we will waive assent.  This is in line with the Patient Care Manual Policy: 
Storage and Release of Mental Healthy Record stating that subjects who are [ADDRESS_155681] provide their own assent for participating in the research study. 
Consent will ideally occur in -person; however, if this is not possible then remote consent will 
occur. Remote consent will take place on a CHOP -approved video conferencing platform, and 
study staff will review all sections of the informed consent form with families. Families will be 
sent a link to our REDCap project with the informed consent form. At the end of the informed consent discussion, families will be asked to e -sign and e -date i n the appropriate sections of the 
REDCap project. An electronic copy of the informed consent form will also be sent to the families for their records.   9.6.1 Waiver of Assen t 
We are requesting a waiver of assent  for all subjects <[ADDRESS_155682] that they are ill or understand the severity of 
their illnesses. Given the high morbidity and mortality rate in AN, requiring adolescent assent could delay treatment.  
 
9.7 Payment to Subjects/Families  
9.7.1 Reimbursement for travel, parking and meals  
Families will be given a parking pass for each visit to Robert’s Center for Pediatric Research so that they do not have to pay for parking.  
 9.7.2 Payments to parent for time and inconvenience (i.e. compensation)  
Time  point 1:  $50/parent for completing questionnaires, neuropsychological assessment, and 
Grocery challenge  
Time point 2:  $10/parent  for completing the questionnaires   
Time point 3:  $25/parent  for completing the questionnaires  and neuropsychological assessment  
Time point 4:  $35/parent for completing questionnaires, neuropsychological assessment, and 
Grocery challenge  
Time point 5:  $50/parent for completing questionnaires, neuropsychological assessment, and 
Grocery challenge  
Time point 6:  $5/parent and $5 for a dolescent for completing questionnaires  
Time point 7:  $5/parent and $[ADDRESS_155683] for time, effort and inconvenience (i.e. compensation)  
 
Time point 1:  $50/subject for completing questionnaires, neuropsychological assessment, and 
Grocery challenge  
Time point 2:  $10/subject  for completing the questionnaires   
Time point 3:  $30/subject  for completing the questionnaires  and neuropsychological assessment  
Time point 4:  $35/subject for completing questionnaires, neuropsychological assessment, and 
Buffet challenge  
Time point 5:  $50/subject for completing questionnaires, neuropsychological assessment, and 
Buffet challenge  
 
9.7.[ADDRESS_155684] phase of a two -phase study (R61/R33 mechanism). We must show improvement 
in the target and meet a -priori Go/No -Go criteria in order  to move forward after year 2. Data 
gathered will initially be used to answer the Go/No -Go question. The publication time line would 
impacted by [CONTACT_137119]. Data will be presented at conferences and published as appropriate.   
 11 REFERENCES  
 
1. Arcelus J, Mitchell AJ, Wales J, Nielsen S. Mortality rates in patients with anorexia nervosa and other eating disorders: 
A meta-analysis of 36 studies. Archives of General Psychiatry. 2011;68(7):724-731.  
2. Franko DL, Keshaviah A, Edd y KT, et al. A longitudinal investigation of mortality in anorexia nervosa and bulimia 
nervosa. American Journal of Psychiatry. 2013;170:917- 925. 
3. Swanson SA, Crow SJ, Le Grange D, Swendsen J, Merikangas KR. Prevalence and correlates of eating disorders in adolescents. Results from the national comorbidity survey replication adolescent supplement. Arch Gen Psychiatry. 
2011;68(7):714- 723. 
4. Treasure J, Russell G. The case for early intervention in anorexia nervosa: theoretical exploration of maintaining 
factors. The British Journal of Psychiatry. 2011;199:5 -7. 
5. Lock J, Le Grange D, Agras WS, Moye A, Bryson SW, Jo B. Randomized clinical trial comparing family -based 
treatment with adolescent -focused individual therapy for adolescents with anorexia nervosa.  Archives of General 
Psychiatry. 2010;67(10):1025- 1032.  
6. Lock J, le Grange D. Treatment Manual for Anorexia Nervosa: A Family -Based Approach.  2nd ed. [LOCATION_001]: 
Guildford Press; 2012.  
7. Loeb KL, le Grange D. Family -based treatment for adolescent eating d isorders: Current status, new applications and 
future directions. International journal of child and adolescent health. 2009;2(2):243.  
8. Loeb KL, Lock J, Greif R, le Grange D. Transdiagnostic theory and application of family-based treatment for youth with eating disorders. Cognitive and Behavioral Practice. 2012;19(1):17 -30. 
9. Nakazato M, Hashimoto K, Schmidt U, et al. Serum glutamine, set -shifting ability and anorexia nervosa. Ann Gen 
Psychiatry. 2010;9:29.  
10. Harper JA, Brodrick B, Van Enkevort E, McAd ams CJ. Neuropsychological and cognitive correlates of recovery in 
anorexia nervosa. European Eating Disorders Review. 2017;25(6):491 -500.  
 page 40    
   11. Tchanturia K, Harrison A, Davies H, et al. Cognitive flexibility and clinical severity in eating disorders. PLoS One. 
2011;6(6):e20462.  
12. Roberts ME, Tchanturia K, Stahl D, Southgate L, Treasure J. A systematic review and meta-analysis of set -shifting 
ability in eating disorders. Psychol Med. 2007;37(8):1075- 1084.  
13. Rößner A, Juniak I, van Noort BM, Pfeiffer E, Lehmkuhl U, Kappel V. Cognit ive Flexibility in Juvenile Anorexia 
Nervosain Relation to Comorbid Symptoms of Depression, Obsessive Compulsive Symptoms and Duration of Illness. 
Zeitschrift für Kinder -und Jugendpsychiatrie und Psychotherapie. 2016.  
14. Andrés -Perpiña S, Lozano -Serra E, Puig O, Lera -Miguel S, Lázaro L, Castro -Fornieles J. Clinical and biological 
correlates of adolescent anorexia nervosa with impaired cognitive profile. European child & adolescent psychiatry. 2011;20(11- 12):541-549.  
15. Calderoni S, Muratori F, Leggero C, et al. Neuropsychological functioning in children and adolescents with restrictive -
type anorexia nervosa: an in- depth investigation with NEPSY -II. J Clin Exp Neuropsychol. 2013;35(2):167- 179. 
16. Lang K, Stahl D, Espie J, Treasure J, Tchanturia K. Set shif ting in children and adolescents with anorexia nervosa: an 
exploratory systematic review and meta-analysis. Int J Eat Disord. 2014;47(4):394-399.  
17. Buhren K, Mainz V, Herpertz-Dahlmann B, et al. Cognitive flexibility in juvenile anorexia nervosa patients  before and 
after weight recovery. J Neural Transm (Vienna). 2012;119(9):1047-1057.  
18. Holliday J, Tchanturia K, Landau S, Collier D, Treasure J. Is impaired set -shifting an endophenotype of anorexia 
nervosa? American Journal of Psychiatry. 2005;162:2269 -2275.  
19. Tchanturia K, Morris RG, Anderluh MB, Collier D, Nikolaou V, Treasure J. Set shifting in anorexia nervosa:  an 
examination before and after weight gain, in full recovery and relationship to childhood and adult OCPD traits. Journal 
of Psychiatric Research. 2004;38:545 -552.  
20. Zastrow A, Kaiser S, Stippi[INVESTIGATOR_69936] C, et al. Neural correlates of impaired cognitive-behavioral flexibility in anorexia nervosa. Am J Psychiatry. 2009;166(5):608- 616. 
21. Best JR, Miller PH. A developmental perspective on executive function. Child development. 2010;81(6):1641- 1660.  
22. Teconi E, Santonastaso P, Degortes D, et al. Set -shifting abilities, central coherence, and handedness in anorexia 
nervosa patients, their u naffected siblings and healthy controls: exploring putative endophenotypes. The World Journal 
of Biological Psychiatry. 2010;11(6):813 -823. 
23. Gottesman II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. American 
Journal of Psychiatry. 2003;160(4):636- 645. 
24. Kjaersdam Telleus G, Fagerlund B, Jepsen JR, et al. Are Weight Status and Cognition Associated? An Examination of Cognitive Development in Children and Adolescents with Anorexia Nervosa [ADDRESS_155685] Rev. 2016;24(5):366- 376. 
25. Tenconi E, Santonastaso P, Degortes D, et al. Set -shifting abilities, central coherence, and handedness in anorexia 
nervosa patients, their unaffected siblings and healthy controls: exploring putative  endophenotypes. The World Journal 
of Biological Psychiatry. 2010;11(6):813 -823. 
26. Galimberti E, Fadda E, Cavallini MC, Martoni RM, Erzegovesi S, Bellodi L. Executive functioning in anorexia nervosa 
patients and their unaffected relatives. Psychiatry Res . 2013;208(3):238-244.  
27. Roberts ME, Tchanturia K, Treasure JL. Exploring the neurocognitive signature [CONTACT_137121] -shifting in anorexia and 
bulimia nervosa. J Psychiatr Res. 2010;44(14):964-970.  
28. Friedman NP, Miyake A. Unity and diversity of executive  functions: Individual differences as a window on cognitive 
structure. Cortex. 2017;86:186 -204. 
29. Sohlberg MM, Turkstra LS. Optimizing cognitive rehabilitation: Effective instructional methods.  [LOCATION_001]: The 
Guildford Press; 2011.  
30. Sohlberg MM, Matter  CA. Cognitive rehabilitation: An integrative neuropsychological approach.  [LOCATION_001]: The 
Guilford Press; 2001.  
31. Ikebuchi E, Sato S, Yamaguchi S, et al. Does improvement of cognitive functioning by [CONTACT_137120]?  A secondary analysis of a randomized controlled trial. Psychiatry Clin 
Neurosci. 2017;71(5):301- 308. 
32. Kim EJ, Bahk Y -C, Oh H, Lee W -H, Lee J -S, Choi K -H. Current status of cognitive remediation for psychiatric 
disorders: A review. Frontiers in Psychiatry. 2018;9:461.  
33. Cicerone KD, Langenbahn DM, Braden C, et al. Evidence-based cognitive rehabilitation: updated review of the 
literature from 2003 through 2008. Archives of physical medicine and rehabilitation. 2011;92(4):519 -530.  
34. Motter JN, Pi[INVESTIGATOR_29826], Rindskopf D, Devanand DP, Doraiswamy PM, Sneed JR. Computerized cogntive training 
and functional recovery in major depressive disorder: A meta-anlaysis. J Affect Disord. 2016;189:184- 191. 
35. Revell ER, Neill JC, Harte M, Khan Z, Drake RJ. A systematic review and meta-analysis of cognitive remediation in early schizophrenia. Schizophrenia research. 2015;168(1-2):213- 222. 
 page [ADDRESS_155686] MW, Bowie CR. A revew of cognitive remediation approaches for schizophrenia: from top- down to bottom -up, 
brain training to psychotherapy. 2017. 2017;17(7):713- 723. 
37. Tchanturia K, Giombini L, Leppanen J, Kinnaird E. Evidence for Cognitive Remediation Therapy in Young People 
with Anorexia Nervosa: Systematic Review and Meta-analysis of the Literature. Eur Eat Disord Rev. 2017;25(4):227-
236. 
38. Tchanturia K, Lounes N, Holttum S. Cognitive remediation in anorexia nervosa and related conditions: a systematic review. Eur Eat Disord Rev. 2014;22(6):454- 462. 
39. Dingemans AE, Danner UN, Donker JM, et al. The eff ectiveness of cognitive remediation therapy in patients with a 
severe or enduring eating disorder: a randomized controlled trial. Psychotherapy and psychosomatics. 2014;83(1):29-
36. 
40. Herbrich L, van Noort B, Pfeiffer E, Lehmkuhl U, Winter S, Kappel V. Follow -up Assessment of Cognitive 
Remediation Therapy in Adolescent Anorexia Nervosa: A Pi[INVESTIGATOR_16116]. Eur Eat Disord Rev. 2017;25(2):104-113.  
41. Le Grange D, Hughes EK, Court A, Yeo M, Cr osby [CONTACT_135569], Sawyer SM. Randomized clinical trial of parent -focused 
treatment and family -based treatment for adolescent anorexia nervosa. Journal of the American Academy of Child & 
Adolescent Psychiatry. 2016;55(8):683-692.  
42. Hughes EK, Sawyer S, Loeb K, le Grange D. Parent -Focused Treatment. In: Loeb K, le Grange D, Lock J, eds. Family 
therapy for adolescent eating and weight disorders . [LOCATION_001]: Routledge; 2015:59-71.  
43. Lock J, Le Grange D, Agras WS, et al. Can adaptive treatment improve outcomes in family -based therapy for 
adolescents with anorexia nervosa? Feasibility and treatment effects of a multi -site treatment study. Behaviour research 
and therapy. 2015;73:90- 95. 
44. Tchanturia K, Lock J. Cognitive remediation therapy for eating disorders: development, refinement and future directions. Behavioral neurobiology of eating disorders : Springer; 2010:269-287.  
45. Tchanturia K, Davies H, Campbell IC. Cognitive remediation therapy for patients with anorexia nervosa: preliminary 
findings. Ann Gen Psychiatry. 2007;6:14.  
46. Pretorius N, Dimmer M, Power E, Eisler I, Simic M, Tchanturia K. Evaluation of a cognitive remediation therapy group for adolescents with anorexia nervosa:  pi[INVESTIGATOR_799]. Eur Eat Disord Rev. 2012;20(4):321- 325. 
47. Wood L, Al -Khairulla H, Lask B. Group cognitive remediation therapy for adolescents with anorexia nervosa. Clinical 
child psychology and psychiatry. 2011;16(2):225- 231. 
48. Dahlgren CL, Lask B, Land ro NI, Ro O. Neuropsychological functioning in adolescents with anorexia nervosa before 
and after cognitive remediation therapy: a feasibility trial. Int J Eat Disord. 2013;46(6):576- 581. 
49. Tchanturia K, Campbell IC, Morris R, Treasure J. Neuropsychologi cal studies in anorexia nervosa. Int J Eat Disord. 
2005;[ADDRESS_155687]:S72-76; discussion S87- 79. 
50. Fitzpatrick KK, Lock JD. Cogntive Remediation Therapy with Children and Adolescents. In: Tchanturia K, ed. Cognitive Remediation Therapy (CRT) for Eating and We ight Disorders. London: Routledge; 2015:111 -129.  
51. Davies H, Tchanturia K. Cognitive remediation therapy as an intervention for acute anorexia nervosa: a case report. European Eating Disorders Review. 2005;13(5):311-316.  
52. Lask B, Roberts A. Family cog nitive remediation therapy for anorexia nervosa. Clin Child Psychol Psychiatry. 
2015;20(2):207- 217. 
53. Butts KA, Floresco SB, Phillips AG. Acute stress impairs set -shifting but not reversal learning. Behav Brain Res. 
2013;252:222- 229. 
54. Orem DM, Petrac DC, Bedwell JS. Chronic self -perceived stress and set -shifting performance in undergraduate 
students. Stress. 2008;11(1):73-78.  
55. Liston C, McEwen BS, Casey BJ. Psychosocial stress reversibly disrupts prefrontal processing and attentional control. 
Proc N atl Acad Sci U S A. 2009;106(3):912- 917. 
56. Ellison R, Rhodes P, Madden S, et al. Do the components of manualized family-based treatment for anorexia nervosa 
predict weight gain? International Jounral of Eating Disorders. 2012;45(4):609- 614. 
57. O’Callagh an CA. OxMaR: Open source free software for online minimization and randomization for clinical  trials. 
PLoS ONE. 2014;9(10):e110761.  
58. Suresh K. An overview of randomization techniques: An unbiased assessment of outcome in clinical research. Journal of human reproductive sciences. 2011;4(1):8-11.  
59. Hoare ZSJ, Whitaker CJ, Whitaker R. Introduction to a generalized method for adaptive randomization in trials. Trials. 2013;14:19- 19. 
60. Wechsler D, Hsiao -pin C. WASI -II: Wechsler abbreviated scale of intel ligence.  Pearson; 2011.  
61. Osterrieth PA. Filetest de copie d'une figure complex: Contribution a l'etude de la perception et de la memoire [The test of copying a complex figure: A contribution to the study of perception and memory]. Archives de Psychologi e. 
1944;30(286-356).  
 page 42    
   62. Rose M, Davis J, Frampton I, Lask B. The Ravello Profile: development of a global standard neuropsychological 
assessment for young people with anorexia nervosa. Clinical child psychology and psychiatry. 2011;16(2):195- 201. 
63. Delis D, Kaplan E, Kramer J. Delis Kaplin Executive Function System.  San Antonio: The Psychological Corporation; 
2001.  
64. Fitzpatrick KK, Darcy A, Colborn D, Gudorf C, Lock J. Set -shifting among adolescents with anorexia nervosa. 
International Journal of Eati ng Disorders. 2012;45(7):909-912.  
65. Gioia GA, Isquith PK, Guy SC, Kenworthy L. Behavior rating inventory of executive function: BRIEF.  Psychological 
Assessment Resources Odessa, FL; 2000.  
66. Vandereycken W. Validity and reliability of the Anorectic Behavior Observation Scale for parents. Acta Psychiatrica 
Scandinavica. 1992;85(2):163-166.  
67. Timko A, Fitzpatrick K. Accommodation and Enabling Scale for Eating Disorders -Revised: A child focused measure 
in preparation.  
68. Sepulveda AR, Kyriacou O, Treasure J. Development and validation of the Accommodation and Enabling Scale for 
Eating Disorders (AESED) for caregivers in eating disorders. BMC Health Services Research. 2009;9:171.  
69. Treasure J, Murphy T, Szmukler GI, Todd G, Gavan K, Joyce J. The experience of caregiving for severe mental illness:  
A comparision between anorexia nerosa and psychosis. Social Psychiatry and Psychiatric Epi[INVESTIGATOR_623]. 2001;36:343-
347. 
 
 
  
 
  
 
  